Abstract
MicroRNAs are small non-coding RNAs with regulatory biological activity, by modulating target genes on epigenetic, transcriptional, post-transciptional and translational levels. Hundreds of reports indicated that miRNAs play important roles in non-small cell lung cancer (NSCLC). Actually, microRNAs are both regulation targets and regulators targeting effector genes. This article reviewed multifaceted role of microRNAs associated to NSCLC, not only targeting to but also targeted by tumor related genes, to help us understand microRNAs related complex regulation networks. Aberrant expressed micoRNAs and their targets were summarized; the statistical results showed that several microRNAs may play key roles by targeting multiple tumor associated targets. On the other hand, Oncogenes and tumor repressors represented by PTEN were also shown to be the most popular targets of microRNAs. Additionally, ZEB1/2 may be a featured pathway in NSCLC, with significant frequency modulated by microRNAs.
Keywords: Regulation mechanism, MicroRNAs, non-coding RNAs, non-small cell lung cancer (NSCLC), tumor, oncogenes.
Current Pharmaceutical Design
Title:Regulation Mechanism of MicroRNAs in Non-Small Cell Lung Cancer
Volume: 23 Issue: 39
Author(s): Feng-Yun Gong, Tao Bai, Ding-Yu Zhang*, Chao-lin Huang, Jing Lv, Jing-Li Wang, Xu-Dong Hu, Juan Wang and Wei Liu
Affiliation:
- Departments of Infectious Diseases Wuhan Medical Treatment Center, Wuhan 430023,China
Keywords: Regulation mechanism, MicroRNAs, non-coding RNAs, non-small cell lung cancer (NSCLC), tumor, oncogenes.
Abstract: MicroRNAs are small non-coding RNAs with regulatory biological activity, by modulating target genes on epigenetic, transcriptional, post-transciptional and translational levels. Hundreds of reports indicated that miRNAs play important roles in non-small cell lung cancer (NSCLC). Actually, microRNAs are both regulation targets and regulators targeting effector genes. This article reviewed multifaceted role of microRNAs associated to NSCLC, not only targeting to but also targeted by tumor related genes, to help us understand microRNAs related complex regulation networks. Aberrant expressed micoRNAs and their targets were summarized; the statistical results showed that several microRNAs may play key roles by targeting multiple tumor associated targets. On the other hand, Oncogenes and tumor repressors represented by PTEN were also shown to be the most popular targets of microRNAs. Additionally, ZEB1/2 may be a featured pathway in NSCLC, with significant frequency modulated by microRNAs.
Export Options
About this article
Cite this article as:
Gong Feng-Yun , Bai Tao , Zhang Ding-Yu *, Huang Chao-lin , Lv Jing , Wang Jing-Li , Hu Xu-Dong , Wang Juan and Liu Wei , Regulation Mechanism of MicroRNAs in Non-Small Cell Lung Cancer, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666170714153424
DOI https://dx.doi.org/10.2174/1381612823666170714153424 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer Activities
Anti-Cancer Agents in Medicinal Chemistry Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review
Mini-Reviews in Medicinal Chemistry Editorial (Hot Topic:Aspergillosis: New Insights into Disease, Diagnostic and Treatment)
Current Pharmaceutical Design Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Current Signal Transduction Therapy DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design Nitroimidazoles as Anti-Tumor Agents
Anti-Cancer Agents in Medicinal Chemistry The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design Current Drug Therapy for Prostate Cancer: An Overview
Current Medicinal Chemistry - Anti-Cancer Agents Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Gastric Ulcer Complicating a Selective Internal Radiation Therapy (SIRT) Procedure for Colorectal Carcinoma Metastasized to the Liver
Current Radiopharmaceuticals Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point
Current Drug Targets Nutrition and NSCLC; Should We Administer Food Supplements?
Current Pharmaceutical Design Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation
Anti-Cancer Agents in Medicinal Chemistry Impact of Antihypertensive Drug Use on Bone Mineral Density and Osteoporotic Fracture - From an Epidemiological Perspective
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Vinorelbine in Cancer Therapy
Current Drug Targets Cancer Cachexia: One Step Ahead
Reviews on Recent Clinical Trials